Pfizer offers Pfizer Oncology Together, a patient support program to help patients access their prescribed Pfizer Oncology medications, identify financial assistance options, and connect patients to a dedicated Care Champion. A complete list of Pfizer Oncology medications and their related assistance programs is provided in the Table.
Pfizer Oncology Together
Pfizer Oncology Together offers the Patient Co-Pay Assistance program, the Pfizer Patient Assistance Program, and the Care Champion Program.
Patient Co-Pay Assistance
Copay savings are available for eligible, commercially insured patients who are prescribed certain Pfizer Oncology oral or injectable medications. Limits, terms, and conditions apply depending on the medication prescribed. Click here to learn more or to enroll your patient in Patient Co-Pay Assistance.
Pfizer Patient Assistance Program
Through the Pfizer Patient Assistance Program, uninsured patients may receive free medication for up to 1 calendar year, while underinsured patients are enrolled through the end of the calendar year. To be evaluated for assistance through this program, you and your patient must each submit a completed enrollment form. Patients must also provide proof of income, such as the prior year’s tax return, a W-2 form, or paycheck stub. Patients must also:
Have a valid prescription from a healthcare provider licensed in the United States or a US territory for a Pfizer medication
Have no prescription coverage, or not enough coverage, to pay for their Pfizer medication
Meet certain income limits, which are subject to change on an annual basis and will vary depending on household size
Reside in the United States or a US territory
Not be treated in an inpatient setting of care, such as a hospital.
Click here to learn more or to enroll your patient in the Pfizer Patient Assistance Program.
Care Champion Program
The Care Champion Program is a free patient support program for patients prescribed a Pfizer Oncology medication. Patients are partnered with a dedicated Care Champion who has social work experience and can provide resources that may help with some of their daily challenges, no matter where they are in the treatment journey. Click here to learn more or to enroll your patient in the Care Champion Program.
Free Trial Vouchers
Patients who have been newly prescribed certain Pfizer Oncology medications may be able to start therapy with a free trial voucher. Click here to learn more or to find out which medications offer trial vouchers, or see Table.
TABLE Pfizer Oncology/Supportive Care Drugs
Patient support programs
Aromasin (exemestane) tablets
Adjuvant treatment of postmenopausal women with ER-positive early breast cancer who have received 2 to 3 years of tamoxifen and are switched to Aromasin for completion of a total of 5 consecutive years of adjuvant hormonal therapy; treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy
Treatment, in combination with binimetinib, of patients with unresectable or metastatic melanoma and a BRAF V600E or V600K mutation, as detected by an FDA-approved test; treatment, in combination with cetuximab, of adults with metastatic colorectal cancer and a BRAF V600E mutation, as detected by an FDA-approved test, after previous therapy
First-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum; treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy
Treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with either an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men, or with fulvestrant in patients with disease progression following endocrine therapy
In combination with avelumab, for the first-line treatment of advanced RCC; in combination with pembrolizumab, for the first-line treatment of advanced RCC; as a single agent, for the treatment of advanced RCC after failure of 1 prior systemic therapy
Treatment of newly diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 1 month and older; treatment of relapsed or refractory CD33-positive AML in adults and pediatric patients 2 years and older
To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia
Treatment of adult patients with GIST after disease progression on or intolerance to imatinib mesylate; treatment of adult patients with advanced RCC; adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy; treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in adult patients with unresectable locally advanced or metastatic disease
Treatment of patients with metastatic NSCLC whose tumors are ALK- or ROS1-positive, as detected by an FDA-approved test; pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large-cell lymphoma that is ALK-positive; adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor that is ALK-positive
To decrease the incidence of infection (ie, febrile neutropenia) in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs; reduce time to neutrophil recovery and fever after chemotherapy in patients with acute myeloid leukemia; reduce duration of neutropenia and neutropenia-related sequelae in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplant; for mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis; to reduce incidence/duration of neutropenia sequelae in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia
Ruxience (rituximab-pvvr) injection Indications
Treatment of adult patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent; previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy; non-progressing, low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone chemotherapy; previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, prednisone, or other anthracycline-based chemotherapy regimens; in combination with fludarabine and cyclophosphamide, for the treatment of adult patients with previously untreated and previously treated CD20-positive chronic lymphocytic leukemia
Report Broken Links
Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?